INGELHEIM, Germany & INDIANAPOLIS — (BUSINESS WIRE) — Empagliflozin reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and…
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
INGELHEIM, Germany & INDIANAPOLIS — (BUSINESS WIRE) — Empagliflozin reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and…